Founded in 2011 and incorporated in France in 2016 Inventiva S. A. is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction associated steatohepatitis (MASH). The company maintains a wholly owned research and development facility in Daix France which houses its laboratory and office spaces. Inventiva S. A. utilizes a team with significant expertise in developing compounds that target nuclear receptors transcription factors and epigenetic modulation to drive its research efforts. The lead product candidate lanifibranor is an orally available small molecule designed to function as a pan peroxisome proliferator activated receptor (PPAR) agonist by stimulating all three PPAR isoforms alpha delta and gamma. This mechanism aims to induce anti inflammatory anti fibrotic and beneficial vascular and metabolic effects in patients with MASH. Following the 2025 Pipeline Prioritization Plan implemented in June 2025 all research and development activities not related to lanifibranor were discontinued including the cessation of the YAP TEAD and NR4A1 programs. Consequently Inventiva S. A. now dedicates all resources to advancing lanifibranor through clinical trials with the objective of demonstrating safety and efficacy for potential regulatory approval and commercialization. As of February 2026 the company employs a development team of 47 individuals to support these activities.

Inventiva S. A. is currently in the clinical development stage and does not generate revenue from product sales as it has no approved therapies on the market. The company's revenue sources are limited to occasional transactions such as asset sales or upfront payments from collaboration agreements. A notable example occurred in December 2025 when Inventiva S. A. entered into an asset purchase agreement with Biossil to sell all rights to its former product candidate odiparcil for the treatment of mucopolysaccharidoses. Under this agreement Inventiva S. A. received an upfront payment of $600,000 and is eligible to receive potential milestone payments totaling up to $90,000,000 upon achievement of specific regulatory and commercial milestones by Biossil. Additionally the agreement includes potential royalties on future sales of odiparcil. Inventiva S. A. has also established collaboration agreements with CTTQ for lanifibranor development in China and with Hepalys for development in the Hepalys Territory however these arrangements do not currently produce revenue as they are focused on clinical development and preparation for potential future commercialization.

Inventiva S. A. operates in a highly competitive market for MASH therapeutics where several major pharmaceutical and biotechnology companies are developing alternative treatments. Prior to 2024 there were no FDA approved therapies specifically for MASH highlighting the significant unmet medical need in this indication. Key competitors now include Madrigal Pharmaceuticals whose drug Rezdiffra received FDA approval in March 2024 for MASH with moderate to advanced liver fibrosis and Novo Nordisk which obtained FDA approval in August 2025 for Wegovy for the treatment of MASH patients with moderate to advanced fibrosis. Numerous other companies are advancing MASH candidates through clinical trials including Boehringer Ingelheim Eli Lilly Akero Therapeutics a subsidiary of Novo Nordisk GSK Roche 89bio Sagimet Boston Pharmaceuticals Altimmune AstraZeneca NorthSea Terns Viking BMS Pfizer Regeneron and Gilead Sciences. Despite this competition Inventiva S. A. believes lanifibranor possesses distinct advantages due to its mechanism as a pan PPAR agonist. Unlike single or dual PPAR agonists lanifibranor activates all three PPAR isoforms alpha delta and gamma simultaneously which the company believes produces a synergistic effect combining anti inflammatory anti fibrotic and beneficial vascular and metabolic improvements. This comprehensive action is supported by preclinical and clinical data showing reductions in liver inflammation fibrosis and steatosis along with improvements in insulin resistance and lipid profiles. For instance in the Phase 2b NATIVE trial lanifibranor at 1200 mg daily met the primary endpoint of reducing inflammation and ballooning without worsening fibrosis after 24 weeks of treatment. Furthermore lanifibranor was the first oral drug candidate to receive Breakthrough Therapy Designation from the FDA for MASH since January 2015 and additionally holds Fast Track Designation which may expedite regulatory review and approval processes.

Inventiva S. A.'s therapeutic focus is on patients suffering from metabolic dysfunction associated steatohepatitis (MASH) a progressive chronic liver disease characterized by fat accumulation inflammation and fibrosis in the liver. The company's target population includes adults with non cirrhotic MASH as well as those with MASH who have progressed to compensated cirrhosis a stage associated with increased risk of liver related complications. Clinical development efforts have also specifically addressed patients with comorbid conditions such as type 2 diabetes as demonstrated in trials like the LEGEND study which evaluated lanifibranor in combination with empagliflozin for non cirrhotic MASH and T2D patients and an investigator initiated trial that assessed lanifibranor in NAFLD and T2D patients. MASH is estimated to affect between two and six percent of the United States adult population representing a significant patient pool for potential therapy. Individuals with MASH face substantially elevated risks including a ten fold increase in liver related mortality compared to the general population and heightened likelihood of requiring liver transplantation or developing liver cancer.